Increased vascular endothelial growth factor in tumor cells and increased production of the receptor for urokinase plasminogen activator in endothelial cells are associated with lymph node metastasis in human breast cancer

Applied Immunohistochemistry

Volumn 7, Issue 1, 1999, Pages 39-47

  Bastholm, Lone ^a   Nielsen, Morten H ^a   Enggaard, Christian ^a   Rank, Fritz ^a   Elling, Folmer ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Angiogenesis; Human breast cancer; Immunoelectron microscopy; Immunohistochemistry; Urokinase plasminogen activator receptor; Vascular endothelial cell growth factor

Indexed keywords

CD31 ANTIGEN; UROKINASE RECEPTOR; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISEASE MARKER; ENDOTHELIUM CELL; FEMALE; HUMAN; IMMUNOELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METASTASIS POTENTIAL; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS REGULATION; TUMOR VASCULARIZATION;

EID: 0032954481     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-199903000-00009     Document Type: Article

References (44)

1. Ellis V, Danø K. The urokinase receptor and the regulation of cell surface plasminogen activation. Fibrinolysis 1992;6:27-34.
2. Costantini V, Sidoni A, Deveglia R, et al. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression. Cancer 1996;77:1079-88.
3. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioassays 1993; 15:105-11.
4. Andreasen PA, Kjoøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
5. Carriero MV, Franco P, Del Vecchio S, et al. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res 1994;54:5445-54.
6. Christensen L, Wiborg Simonsen AC, Heegaard CW, et al. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas. Int J Cancer 1996;66:441-52.
7. Pyke C, Graem N, Ralfkiaer E, et al. Receptor for urokinase plasminogen activator is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993;53:1911-5.
8. Hildebrand R, Dilger I, Horlin A, Stutte HJ. Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer. Pathol Res Pract 1995;191:403-9.
9. Grondahl-Hansen J, Peters HA, van Putten WLJ, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995;1:1079-87.
10. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
11. Weidner N. Intratumor micro vessel density as a prognostic factor in cancer [comment]. Am J Pathol 1995;147:9-19.
12. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
13. Vermeulen PB, Libura J, Libura M, et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Nat Cancer Inst 1995;87:1797-8.
14. Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 1993;55:371-4.
15. Weidner N. Current pathologic methods for measuring intratumoral micro vessel density within breast carcinoma and other solid tumors [Review]. Breast Cancer Res Treat 1995;36:169-80.
16. Axelsson K, Ljung B-ME, More II DH, et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Nat Cancer Inst 1995;87:997-1008.
17. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of micro vessel density, Chalkley count, and computer image analysis. J Pathol 1995;177:275-83.
18. Goulding H, Abdul Rashid NF, Robertson JF, et al. Assessment of angiogenesis in breast carcinoma: an important factor in prognosis? Human Pathol 1995;26:1196-200.
19. Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995;36:193-204.
20. Weidner N, Folkman J. Tumoral vascularity as prognostic factor in cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: Lippincott-Raven; 1996:167-90.
21. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32A:2474-84.
22. Hinsbergh vVWM, Kooistra T, Koolwijk P. The vascular fibrinolytic system: pathophysiological modulation. Fibrinolysis 1993;7 (suppl 1):11-6.
23. Mignatti P. The fibrinolytic system and angiogenesis. Fibrinolysis 1993;7:20-1.
24. Senger DR. Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. Am J Pathol 1996;149:1-7.
25. Pepper MS, Sappino AP, Stocklin R, Montesano R, Orci L, Vassalli JD. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 1993;122:673-84.
26. Schnaper HW, Barnathan ES, Mazar A, et al. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol 1995;165:107-18.
27. Lu H, Mabilat C, Yeh P, et al. Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells. FEBS Lett 1996;380:21-4.
28. Scarff R, Torloni H. Histologic typing of breast tumours. Geneva: World Health Organization, 1968:12-20.
29. Bloom H, Richardson W. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-77.
30. van den Pol AN. Silver-intensified gold and peroxidase as dual ultrastructural immunolabels for pre- and postsynaptic neurotransmitters. Science 1997;228:332-5.
31. Riesenberg R, Oberneder R, Kriegmair M, et al. Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells. Histochemistry 1993;99: 61-6.
32. Danscher G. Localization of gold in biological tissue. Histochemistry 1981;71:81-8.
33. Tokuyasu KT. Immunochemistry on ultrathin sections. Histochem J 1980;12:381-403.
34. Tokuyasu KT. Application of cryoultramicrotomy to immunocytochemistry. J Microsc 1986;143:139-49.
35. Griffiths G, McDowall A, Back R, Dubochet J. On the preparation of cryosections for immunocytochemistry. J Ultrastruct Res 1989; 89:65-78.
36. Bastholm L, Elling F, Brunner N, Nielsen MH. Immunoelectron microscopy of the receptor for urokinase plasminogen activator and cathepsin D in the human breast cancer cell line MDA-MB-231. APMIS 1998;102:279-86.
37. Bastholm L, Elling F. Thin cryosections and immunogold-silver staining. In: Hayat MA, ed. Immunogold-silver staining. Principles, methods, and applications. Boca Raton: CRC Press, 1995: 149-62.
38. Moriyama M, Kumagai S, Kawashiri S, Kojima K, Kakihara K, Yamamoto E. Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 1997;33:369-74.
39. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 1996;15:165-76.
40. Senger DR, Brown LF, Claffey KP, Dvorak HF. Vascular permeability factor, tumor angiogenesis and stroma generation. Invasion Metastasis 1994;14:385-94.
41. Brown LF, Detmar M, Claffey K, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997;79:233-69.
42. Yeo T-K, Dvorak HF. Tumor stroma. In: Colvin RB, Bhan AK, McCluskey RT, eds. Diagnostic immunopathology, 2nd ed. New York: Raven Press, 1995:685-97.
43. Lu H, Mabilat C, Yeh P, et al. Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells. FEBS Lett 1996;380:21-4.
44. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;90:404-7.